Skip to content
Triangle logo TriangleGet started
← Full study record

NCT02283658 · OUTCOME

Overall Suravival(OS)

Everolimus and Letrozole in Treating Patients With Recurrent Hormone Receptor Positive Ovarian, Fallopian Tube, or Primary Peritoneal Cavity Cancer · Source last updated 2020-10-23

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
MEDIAN
Unit
Months
Interval / dispersion
95% Confidence Interval
Time frame
Time from registration to death from any cause, assessed up to 2 years

What was measured

OS will be estimated using the method of Kaplan-Meier.

Analysis population: All evaluable patients

Groups in this outcome

Treatment (Everolimus and Letrozole)

Patients receive everolimus PO QD and letrozole PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Treatment (Everolimus and Letrozole)19

Reported measurements

Source class 1
Values in Months · Interval/dispersion: 95% Confidence Interval
GroupValueSpreadLowerUpperComment
Treatment (Everolimus and Letrozole)13Not reported8.8NANot Reached;Median was not reached due to too few PFS events.
Complete source fields
classes
  1. categories
    1. measurements
      1. comment
        Not Reached;Median was not reached due to too few PFS events.
        group Id
        OG000
        lower Limit
        8.8
        upper Limit
        NA
        value
        13
denoms
  1. counts
    1. group Id
      OG000
      value
      19
    units
    Participants
description
OS will be estimated using the method of Kaplan-Meier.
dispersion Type
95% Confidence Interval
groups
  1. description
    Patients receive everolimus PO QD and letrozole PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
    id
    OG000
    title
    Treatment (Everolimus and Letrozole)
param Type
MEDIAN
population Description
All evaluable patients
reporting Status
POSTED
time Frame
Time from registration to death from any cause, assessed up to 2 years
title
Overall Suravival(OS)
type
SECONDARY
unit Of Measure
Months

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice